NOVOCURE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.01 USD | -1.17% |
|
-4.92% | +47.42% |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- The company's enterprise value to sales, at 3.91 times its current sales, is high.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +47.42% | 2.37B | C- | ||
| +75.69% | 12.57B | B- | ||
| -24.68% | 7.34B | C+ | ||
| +6.22% | 6.61B | C- | ||
| +12.58% | 5.39B | D+ | ||
| +26.90% | 4.53B | - | ||
| -21.14% | 3.91B | B- | ||
| -22.99% | 2.91B | C | ||
| -0.37% | 2B | - | ||
| +6.21% | 1.91B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- NVCR Stock
- Ratings NovoCure Limited
